SETD2 and myeloproliferative disorder: We recently described BETi-persister/resistant (BETi-P/R) post-MPN sAML and AML cells (SET-2-OTX P/R, HEL-OTX P/R, and THP1-OTX P/R cells) that displayed nongenetic mechanism of BETi-resistance, based on increased expression and activity of β-catenin-TCF7L2-JMJD6-c-Myc (Fig. S16A)33.